TC
ADMA icon

TwinBeech Capital’s ADMA Biologics ADMA Stock Holding History

TwinBeech Capital’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$531K Sell
63,434
-158,407
-71% -$1.44M 0.1% 221
2026
Q1 		$2M Buy
221,841
+180,541
+437% +$2.85M 0.21% 143
2025
Q4 		$753K Sell
41,300
-35,934
-47% -$606K 0.05% 348
2025
Q3 		$1.13M Sell
77,234
-206,093
-73% -$3.53M 0.04% 296
2025
Q2 		$5.16M Buy
+283,327
New +$5.78M 0.12% 201
2025
Q1 		– Sell
-214,710
Closed -$3.68M – 684
2024
Q4 		$3.68M Buy
+214,710
New +$4.04M 0.06% 267

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

TwinBeech Capital's ADMA Position: Q2 2026 in Review

TwinBeech Capital reduced its ADMA Biologics (ADMA) stake by 71% in Q2 2026, selling an estimated $1.44M and leaving 63,434 shares worth $531K. The position accounts for 0.1% of the portfolio, ranked #221.

TwinBeech Capital first reported a position in ADMA in Q4 2024 and has held it in 6 quarters since. The position peaked at $5.16M in Q2 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • TwinBeech Capital held 63,434 shares of ADMA Biologics worth $531K as of Q2 2026.
  • TwinBeech Capital sold 158,407 ADMA Biologics shares in Q2 2026, an estimated $1.44M.
  • ADMA Biologics made up 0.1% of TwinBeech Capital's portfolio in Q2 2026, its #221 holding.
  • TwinBeech Capital first reported a position in ADMA Biologics in Q4 2024 and has held it in 6 quarters since.
  • TwinBeech Capital's ADMA Biologics position peaked at $5.16M in Q2 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on TwinBeech Capital's 13F filing for Q2 2026, filed 14 Aug 2026.